Week in Review: Zai Lab Raises $750 Million in Private Placement for In-Licensed/Novel Drugs

Deals and Financings   Shanghai Zai Lab raised an impressive $750 million in a private placement of its dual US/Hong Kong stock for its in-licensing and novel drug development operations; Beijing's EdiGene completed a $62 million Series B Plus financing to support its gene editing drug portfolio, including a clinical stage CRISPR/Cas 9 therapy;  Suzhou Porton Biologics, a gene and cell therapy CDMO service company, closed a $61 million Series A funding to build Phase II of its plant; Shanghai Junshi Bio invested $50 million into its  US  partner, Coherus, which had signed a $1.1 billion deal to develop Junshi's PD-1 drug in the US ; Ronovo Surgical, a  Shanghai  company developing novel minimally invasive and digital surgery devices, completed a Series A financing;   COVID-19 Pandemic   Tianjin CanSino Biologics will start a clinical trial of an inhaled COVID-19 vaccine in  China ; RNAImmune, a spinout from Sirnaomics, raised $10 million in seed capital to develop mRNA therapeutics and vaccines including a COVID-19 mRNA vaccine; Trials and Approvals Shanghai Henlius Biotech said the NDA for its novel anti-PD-L1 candidate has been accepted for review by  China 's NMPA for solid tumor cancers; Shanghai Junshi Biosciences stopped the Phase III trial of its anti-PD-1 candidate early because toripalimab met its survival endpoints; Transcenta Holding, a  Suzhou  biopharma, was approved to start a US Phase I trial of its bi-functional anti-PD-L1/TGF-β antibody in patients with solid tumors; Company News Shanghai 's PhageLux, an antimicrobial company, announced its agricultural division acquired a new manufacturing facility in Yixing,  Wuxi . Stock Symbols: (NSDQ: ZLAB; HK: 9688) (HK: 1877; SHA: 688180) (NSDQ:CHRS) (HK: 6185; SHA: 688185) (HK:2696) (HK: 1877; SHA: 688180) Share this with colleagues: // //